Targeted radiotherapeutics (TRT) are precision medicines that deliver radiation to kill cancer cells. Our novel platform is based on a proprietary modular design to increase efficacy and safety by increasing delivery to tumors while sparing normal tissues.

Cereius is developing a clinical pipeline to address both brain and peripheral solid tumors. CER-101 is our lead candidate designed to deliver targeted radiation to breast cancer brain metastases.

Cereius is led by a team with a deep understanding of the biology of cancer and extensive drug discovery and development experience.

Targeted radiotherapeutics combine the precision of targeted molecules with the power of radiation treatment. Read more about TRTs and the uses of radiation therapy.